drug · protein
Ozempic
pre_registrationupdated 5mo agoby Novo Nordisk AS🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugWegovy222 co-mentions · 76 sources
- tagApproval176 co-mentions · 44 sources
- drugWegovy Pill168 co-mentions · 74 sources
- drugRybelsus121 co-mentions · 73 sources
- drugsemaglutide120 co-mentions · 72 sources
- tagSmall Molecule35 co-mentions · 18 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc23 co-mentions · 4 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
targets
Glucagon-like peptide 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying Ozempic
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
- —Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
- phase4Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- phase3A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- phase1A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
- phase3A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- phase3A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- phase2A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
News(10)
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 2d ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 3d ago
- Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsPatients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.biospace · 3d ago
- #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapyMILAN — Regeneron’s investigational drug helped obesity patients who stopped taking Novo’s Wegovy regain a similar amount of muscle mass to what they lost when they took the GLP-1, according to new…endpoints · 3d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 4d ago
- Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…biospace · 4d ago
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetesMILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…endpoints · 4d ago
- Lilly builds commercial case for GLP-1 products over Novo with indirect analysesEli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…biospace · 4d ago
- Lilly raises diabetes weight-loss bar with amylin-Zepbound comboEli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…fiercebiotech · 4d ago
- FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution SchemeThe U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramanc…fda_press · 5d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that